Candel Therapeutics, Inc. - Common Stock (CADL)

Competitors to Candel Therapeutics, Inc. - Common Stock (CADL)

Adaptimmune Therapeutics PLC 

Adaptimmune applies engineered T-cell therapies to target cancer cells, creating a forefront in the immunotherapy landscape. Candel Therapeutics also focuses on immunotherapy, particularly in harnessing oncolytic virus platforms. While both companies share a common goal of developing cancer therapies, Adaptimmune's established platform and pipeline in T-cell therapy give it a competitive advantage within specific niches of cancer treatment.

Bluebird Bio, Inc. 

Bluebird Bio focuses on developing innovative gene therapies for various genetic diseases and cancer, positioning itself in the field of precision medicine. Both Candel Therapeutics and Bluebird Bio aim to harness advanced biotechnological approaches to create treatments, particularly in oncology, creating competition for market share and investment. Bluebird has garnered more extensive partnerships and funding historically, providing them with a competitive edge in research and clinical trials.

Immune-Onc Therapeutics

Immune-Onc Therapeutics develops novel immunotherapies for a variety of cancers, overlapping significantly with Candel's focus on immunotherapies utilizing oncolytic viruses. Both companies are competing to establish clinical proof-of-concept and bring unique therapies to market. While Immune-Onc is still in earlier developmental stages, if successful, they could present a challenge in the evolving landscape of cancer therapies.

Marathon Pharmaceuticals, LLC

Marathon Pharmaceuticals is dedicated to treating rare and serious diseases through innovative therapeutic approaches, which may include avenues similar to those explored by Candel in oncology. While Marathon's focus on rare conditions may differ, its aggressive pursuit of novel therapeutics places it in a competitive space, particularly as both seek to attract similar investor segments interested in groundbreaking medical treatments.

Oncorus, Inc.

Oncorus develops oncolytic virus therapies that aim to selectively kill cancer cells, aligning closely with the mission of Candel Therapeutics. Both firms focus on the same therapeutic area using similar technology, intensifying competition. However, Oncorus has made rapid progress in clinical trials, which may give them a greater visibility and first-mover advantage in market penetration.